INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
Report Outlook
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 6.08 Billion by 2030 | 5.10% | North America |
| By Product | By Reagents | By Application | By End Use |
|---|---|---|---|
|
|
|
|
SCOPE OF THE REPORT
PreClinical Imaging Market Overview
The global PreClinical Imaging market is expected to grow from USD 4.30 Billion in 2023 to USD 6.08 Billion by 2030, at a CAGR of 5.10 % during the forecast period.
Preclinical imaging constitutes a niche within biomedical research, employing non-invasive imaging techniques to observe and analyze biological phenomena, anatomical features, and disease processes in preclinical subjects, often involving small animals like mice and rats. This field is critical for furthering our understanding of illnesses, evaluating prospective therapeutics, and optimizing drug development procedures. The use of magnetic resonance imaging (MRI), PET (positron emission tomography), single-photon emission computed tomography (SPECT), computed tomography (CT), bioluminescence imaging (BLI), fluorescence imaging, and optical imaging are all examples of preclinical methods for imaging.
Preclinical imaging is used by researchers and pharmaceutical firms to acquire vital insights on disease development, monitor therapy responses, and assess the safety and effectiveness of innovative medications and treatments. Preclinical imaging aids in the identification of potential drug targets, the validation of experimental models, as well as the optimisation of therapeutic interventions by visualizing and quantifying biological phenomena like gene expression, molecular interactions, tissue morphology, and physiological functions. It also allows for longitudinal investigations, reducing the demand for intrusive treatments and assuring ethical animal study treatment.
The rising frequency of chronic illnesses such as cancer, cardiovascular disease, and neurological problems is fueling demand for PreClinical Imaging technology. These imaging techniques are important for understanding disease processes, identifying prospective therapeutic targets, and assessing the safety and effectiveness of new medications and therapies. As the worldwide burden of chronic illnesses continues to rise, PreClinical Imaging remains an essential research and therapeutic tool. In addition, in the PreClinical Imaging market, the drive towards personalized treatment is a driving force. The rising knowledge that individual individuals may respond differently to therapies needs a better understanding of disease heterogeneity and more personalized therapeutic approaches. PreClinical Imaging allows researchers to examine disease subtypes, predict therapy responses, and pick the most promising individuals for clinical trials, all while aligning with personalized healthcare goals.
Furthermore, the incorporation of sophisticated technologies including artificial intelligence, machine learning, and radiomics is transforming the PreClinical Imaging scene. These technologies accelerate research processes and enable data-driven decision-making by improving data processing, automating picture interpretation, and providing quantitative insights.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2030 |
| Base year | 2022 |
| Estimated year | 2023 |
| Forecasted year | 2023-2030 |
| Historical period | 2019-2021 |
| Unit | Value (USD Billion) Volume (Thousand Units) |
| Segmentation | By Product, Reagents, Application, End Use and Region |
| By Product |
|
| By Reagents |
|
| By Application |
|
| By End Use |
|
| Â
By Region  |
|
PreClinical Imaging Market Segmentation Analysis
The global PreClinical Imaging market is divided into four segments, product, Reagents, Application, end use and region. By product the market is divided into Optical Imaging Systems, Nuclear Imaging Systems, Micro-MRI systems, Micro-ultrasound systems, Micro-CT systems, PreClinical Photoacoustic Imaging Systems, PreClinical Magnetic Particle Imaging Systems. By Reagents the market is divided into PreClinical Optical Imaging Reagents, PreClinical Nuclear Imaging Reagents, PreClinical MRI Contrast Agents, PreClinical Ultrasound Contrast Agents, PreClinical CT Contrast Agents. By Application the market is classified into Application, Research and development, Drug discovery, Bio-distribution, Cancer cell detection, Bio-markers, Others. By end use the market is classified into Contract research organizations (CROs), Pharmaceutical and biotechnology companies, Academic and government research institutes, Diagnostic centers, Others.
Based on product optical imaging systems segment dominating in the PreClinical Imaging market. Light is used in optical imaging systems to see and monitor biological activities at the molecular level. They’re non-invasive and may be used to capture real-time images of tiny animals. As a result, they are appropriate for a variety of preclinical research applications, such as as drug discovery and development, toxicological testing, and regenerative medicine. Some of the primary reasons for optical imaging technologies’ prominence is their ability to see molecular and cellular activities with outstanding sensitivity and precision. For instance, bioluminescence imaging allows researchers to follow biological processes by detecting the light generated by bioluminescent reporter genes within live organisms. This approach provides real-time molecular monitoring of gene expression, cell tracking, and disease development, bringing crucial insights into preclinical investigations.
Fluorescence imaging, on the other hand, uses fluorescent probes and markers to attach to particular molecules or cellular structures of interest. In vivo visualization of cellular processes, protein interactions, and disease-related alterations is possible using this technique. Researchers may employ a variety of fluorescent labels to target individual molecules, allowing them to examine disease causes and therapy responses in great detail.
Based on application, research and development segment dominating in the PreClinical Imaging market. Preclinical imaging, first and foremost, is a cornerstone of early-phase research, allowing scientists and pharmaceutical firms to obtain critical insights into disease processes, treatment effectiveness, and security profiles of potential drug candidates. Preclinical imaging modalities such as MRI, PET, SPECT, CT, and optical imaging are used by researchers to visualise and monitor physiological processes, tissue architecture, and molecular interactions within living animals.
Furthermore, preclinical imaging plays an important role in the validation and optimisation of experimental models. Animal models, including mice and rats, are frequently used to imitate human illnesses and evaluate the efficacy of experimental medicines. Preclinical imaging enables non-invasive, long-term monitoring of these models, making it easier to analyse disease progression and therapy responses. Researchers may make more informed judgements on model selection and refining, which improves the relevance and applicability of their results in clinical settings.
Moreover, the utilization of specialized imaging reagents and contrast agents contributes to the overall cost of preclinical imaging studies. These substances play a crucial role in enhancing the precision and sensitivity of imaging techniques, especially in the domains of molecular and functional imaging. The development and production of these agent’s entail rigorous quality control measures and strict adherence to regulatory standards, further amplifying their expenses.
PreClinical Imaging Market Dynamics
Driver
Advancements in imaging technology is driving PreClinical Imaging market.
The development of multimodal imaging systems, which combine different imaging modalities on a single platform. Magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and optical imaging are all used in these systems. This integration enables researchers to acquire a multitude of data, providing a more comprehensive perspective of biological processes and improving preclinical study accuracy.
A different important innovation is molecular imaging. It makes it possible to see and monitor individual chemicals, genes, or cells within live organisms. This technique is extremely useful for investigating molecular and cellular processes, tracking disease development, and determining the efficacy of targeted medicines. Molecular imaging agents, such as nanoparticles and molecular markers, improve imaging specificity and sensitivity, allowing for more accurate molecular observations. Furthermore, high-resolution imaging is becoming more affordable. Researchers can now record precise features at the cellular and subcellular levels because to improved technology and procedures.
Restraint
High cost of preclinical imaging systems and reagents can impede the PreClinical Imaging market during the forecast period.
Developing and producing cutting-edge preclinical imaging systems necessitates significant research and engineering expenses. These systems are built to fulfil the most severe performance requirements, with high-resolution imaging, multi-modality capabilities, and real-time monitoring. These gains come at a cost that reflects the time and investment necessary to produce those complex tools. Furthermore, the upkeep and calibration of preclinical imaging equipment necessitate constant expenditure. Maintaining these systems at top performance levels involves regular service and upgrades, which raises the overall cost of ownership. These charges are especially important for major research institutes and pharmaceutical corporations that have considerable preclinical imaging equipment.
In addition, the usage of specialised imaging reagents and contrast agents adds to the overall expense of preclinical imaging investigations. These chemicals are critical for improving imaging method specificity and sensitivity, particularly in molecular and functional imaging. The research and manufacture of these agents need stringent quality control and adherence to regulatory norms, which adds to their cost.
Opportunities
Growing demand for personalized medicine is creating new opportunities for the PreClinical Imaging market.
Personalized medicine is strongly reliant on a thorough understanding of illnesses’ molecular and genetic basis. Researchers may see and track individual molecules, genes, or biological processes within living creatures using preclinical imaging technologies, especially molecular imaging and functional imaging modalities. This skill is useful for finding illness biomarkers, comprehending disease processes, and evaluating the efficacy of targeted medicines. Preclinical imaging aids in the discovery of personalized therapy options by offering precise insights into disease processes at the molecular level.
In addition, preclinical imaging is critical in the development and validation of innovative therapeutic agents such as targeted medicines and biologics. Preclinical imaging is used by researchers to analyses the pharmacokinetics, biodistribution, and therapeutic effectiveness of various medicines in preclinical animals. This information is critical for identifying among the most promising treatment candidates for clinical trials and forecasting their effectiveness in certain patient populations.
Radiomics, a science that extracts quantitative information from medical pictures, is growing in popularity, and it is strongly related to personalized medicine. Preclinical imaging offers a lot of data that may be used to find imaging biomarkers linked with therapy response, disease progression, and patient prognosis utilizing radiomic methods. In a personalized medicine paradigm, these indicators are excellent tools for personalizing treatment approaches and predicting patient outcomes.
PreClinical Imaging Market Trends
- Artificial intelligence (AI) and machine learning are being used to analyses preclinical imaging data. These technologies improve picture interpretation automation, speed, and accuracy, and can aid in illness identification and therapy assessment.
- Three-dimensional imaging methods are becoming increasingly prominent due to their potential to give a more complete knowledge of anatomical and functional changes in preclinical animals. This tendency makes it easier to visualize complicated structures and disease processes.
- Preclinical imaging is increasingly being utilised in drug development to evaluate potential drug candidates’ effectiveness, safety, and toxicity. This trend simplifies drug discovery by minimizing reliance on animal models and human trials.
- The usage of small animal models in preclinical investigations is increasing, boosting the demand for high-resolution imaging equipment designed specifically for tiny animals. These devices allow researchers to more effectively replicate human illness situations.
- For preclinical research, new imaging methods like as photoacoustic imaging and magnetic particle imaging are being developed. These technologies outperform standard imaging techniques in terms of resolution and sensitivity.
- Multimodality imaging systems combine two or more imaging modalities to offer a more comprehensive view of the physiology of an animal. Since they may give more information than any single imaging modality, multimodality imaging devices are becoming increasingly popular in the preclinical imaging industry.
Competitive Landscape
The competitive landscape of the PreClinical Imaging market was dynamic, with several prominent companies competing to provide innovative and advanced PreClinical Imaging solutions.
- Bruker Corporation
- Siemens Healthineers
- General Electric Healthcare
- PerkinElmer, Inc.
- VisualSonics Inc.
- Mediso Ltd.
- Agilent Technologies, Inc.
- MILabs B.V.
- MR Solutions Ltd.
- TriFoil Imaging, Inc.
- Molecubes
- Aspect Imaging
- Li-COR Biosciences, Inc.
- XACT Robotics
- Bruker BioSpin
- Concorde Microsystems
- FUJIFILM Healthcare Americas
- GE Research
- IBA Group
- MILabs
Recent Developments:
Sep 14, 2023: Mayo Clinic and GE HealthCare announced a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.
January 5, 2023: Bruker Corporation announced the acquisition of ACQUIFER Imaging GmbH, a pioneer in big-data management solutions for bioimaging and high-content microscopy. This acquisition adds high-performance on-premise processing, secure storage and networking technology that complements Bruker’s advanced fluorescence microscopy imaging products, such as light-sheet and super-resolution microscopy products, which generate high information content.
Regional Analysis
North America accounted for the largest market in the PreClinical Imaging market. North America accounted for the 37 % market share of the global market value. Â North America has a thriving and vibrant biomedical research ecosystem, with several university institutions, research centres, and pharmaceutical corporations actively involved in preclinical research. With the existence of these research institutions, there has always been a considerable need for preclinical imaging technology and services. Additionally, significant investments in healthcare and life sciences have enabled the region to acquire powerful preclinical imaging technologies and perform cutting-edge research. Government financing, corporate investments, and academic partnerships all contribute to the expansion of the North American PreClinical Imaging industry. Also, North America is at the cutting edge of technological innovation, always pushing the limits of preclinical imaging modalities. The region’s focus has been on the development of sophisticated imaging techniques such as molecular imaging, optical imaging, and functional MRI.
The APAC PreClinical Imaging market is contributing significantly to worldwide research efforts. China, Japan, South Korea, and India, among other APAC nations, have made considerable expenditures in biomedical research, drawing talent and encouraging relationships with worldwide research organisations. This has culminated in an increase in preclinical investigations, which in turn has increased demand for preclinical imaging technology. Furthermore, the pharmaceutical and biotechnology sectors in APAC are expanding rapidly, owing to reasons such as ageing populations, changing illness profiles, and growing healthcare expenditures.
Target Audience for PreClinical Imaging Market
- Preclinical Imaging Instrument Manufacturers, Suppliers, and Imaging Software Providers
- Pharmaceutical and Biotechnology Companies
- Preclinical Imaging Reagent Manufacturers and Suppliers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Import & Export Data for PreClinical Imaging Market
Exactitude consultancy provides import and export data for the recent years. It also offers insights on production and consumption volume of the product. Understanding the import and export data is pivotal for any player in the PreClinical Imaging market. This knowledge equips businesses with strategic advantages, such as:
- Identifying emerging markets with untapped potential.
- Adapting supply chain strategies to optimize cost-efficiency and market responsiveness.
- Navigating competition by assessing major players’ trade dynamics.
Key insights
- Trade volume trends: our report dissects import and export data spanning the last five years to reveal crucial trends and growth patterns within the global PreClinical Imaging This data-driven exploration empowers readers with a deep understanding of the market’s trajectory.
- Market players: gain insights into the leading players driving the PreClinical Imaging From established giants to emerging contenders, our analysis highlights the key contributors to the import and export landscape.
- Geographical dynamics: delve into the geographical distribution of trade activities. Uncover which regions dominate exports and which ones hold the reins on imports, painting a comprehensive picture of the industry’s global footprint.
- Product breakdown: by segmenting data based on PreClinical Imaging types –– we provide a granular view of trade preferences and shifts, enabling businesses to align strategies with the evolving technological landscape.
Import and export data is crucial in reports as it offers insights into global market trends, identifies emerging opportunities, and informs supply chain management. By analyzing trade flows, businesses can make informed decisions, manage risks, and tailor strategies to changing demand. This data aids government in policy formulation and trade negotiations, while investors use it to assess market potential. Moreover, import and export data contributes to economic indicators, influences product innovation, and promotes transparency in international trade, making it an essential component for comprehensive and informed analyses.
Segments Covered in the PreClinical Imaging Market Report
  PreClinical Imaging Market by Product
- Optical Imaging Systems
- Nuclear Imaging Systems
- Micro-MRI systems
- Micro-ultrasound systems
- Micro-CT systems
- PreClinical Photoacoustic Imaging Systems
- PreClinical Magnetic Particle Imaging Systems
  PreClinical Imaging Market by Reagents
- PreClinical Optical Imaging Reagents
- PreClinical Nuclear Imaging Reagents
- PreClinical MRI Contrast Agents
- PreClinical Ultrasound Contrast Agents
- PreClinical CT Contrast Agents
  PreClinical Imaging Market by Application
- Research and development
- Drug discovery
- Bio-distribution
- Cancer cell detection
- Bio-markers
- Others
  PreClinical Imaging Market by End Use
- Contract research organizations (CROs)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Diagnostic centers
- Others
  PreClinical Imaging Market by Region
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Key Question Answered
- What is the expected growth rate of the preclinical imaging market over the next 7 years?
- Who are the major players in the PreClinical Imaging market and what is their market share?
- What are the end use industries driving market demand and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-Pacific, the middle east, and Africa?
- How is the economic environment affecting the PreClinical Imaging market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the PreClinical Imaging market?
- What is the current and forecasted size and growth rate of the global PreClinical Imaging market?
- What are the key drivers of growth in the PreClinical Imaging market?
- Who are the major players in the market and what is their market share?
- What are the distribution channels and supply chain dynamics in the PreClinical Imaging market?
- What are the technological advancements and innovations in the PreClinical Imaging market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the PreClinical Imaging market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the PreClinical Imaging market?
- What are the product offerings and specifications of leading players in the market?
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA SOURCES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL PRECLINICAL IMAGING MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON PRECLINICAL IMAGING MARKET
- PORTER’S FIVE FORCES MODEL
- THREAT FROM NEW ENTRANTS
- THREAT FROM SUBSTITUTES
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF CUSTOMERS
- DEGREE OF COMPETITION
- INDUSTRY VALUE CHAIN ANALYSIS
- GLOBAL PRECLINICAL IMAGING MARKET OUTLOOK
- GLOBAL PRECLINICAL IMAGING MARKET BY PRODUCT, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- OPTICAL IMAGING SYSTEMS
- NUCLEAR IMAGING SYSTEMS
- MICRO-MRI SYSTEMS
- MICRO-ULTRASOUND SYSTEMS
- MICRO-CT SYSTEMS
- PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS
- PRECLINICAL MAGNETIC PARTICLE IMAGING SYSTEMS
- GLOBAL PRECLINICAL IMAGING MARKET BY REAGANT, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- PRECLINICAL OPTICAL IMAGING REAGENTS
- PRECLINICAL NUCLEAR IMAGING REAGENTS
- PRECLINICAL MRI CONTRAST AGENTS
- PRECLINICAL ULTRASOUND CONTRAST AGENTS
- PRECLINICAL CT CONTRAST AGENTS
- GLOBAL PRECLINICAL IMAGING MARKET BY APPLICATION, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- RESEARCH AND DEVELOPMENT
- DRUG DISCOVERY
- BIO-DISTRIBUTION
- CANCER CELL DETECTION
- BIO-MARKERS
- OTHERS
- GLOBAL PRECLINICAL IMAGING MARKET BY END-USE, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- CONTRACT RESEARCH ORGANIZATIONS (CROS)
- PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
- ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
- DIAGNOSTIC CENTERS
- OTHERS
- GLOBAL PRECLINICAL IMAGING MARKET BY REGION, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- NORTH AMERICA
- US
- CANADA
- MEXICO
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- EUROPE
- GERMANY
- UK
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA PACIFIC
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES*
(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCTS OFFERED, RECENT DEVELOPMENTS)
- BRUKER CORPORATION
- SIEMENS HEALTHINEERS
- GENERAL ELECTRIC HEALTHCARE
- PERKINELMER, INC.
- VISUALSONICS INC.
- MEDISO LTD.
- AGILENT TECHNOLOGIES, INC.
- MILABS B.V.
- MR SOLUTIONS LTD.
- TRIFOIL IMAGING, INC.
- MOLECUBES
- ASPECT IMAGING
- LI-COR BIOSCIENCES, INC.
- XACT ROBOTICS
- BRUKER BIOSPIN
- CONCORDE MICROSYSTEMS
- FUJIFILM HEALTHCARE AMERICAS
- GE RESEARCH
- IBA GROUP
- MILABS
*THE COMPANY LIST IS INDICATIVE
LIST OF TABLES
TABLE 1Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 2Â Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 3Â Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 4Â Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 5Â Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 6Â Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 7Â Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 8Â Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 9Â Â Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY REGION (USD BILLION) 2020-2030
TABLE 10Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY REGION (THOUSAND UNITS) 2020-2030
TABLE 11Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 12Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 13Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 14Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 15Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 16Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 17Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 18Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 19Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 20Â Â Â NORTH AMERICA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 21Â Â Â US PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 22Â Â Â US PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 23Â Â Â US PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 24Â Â Â US PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 25Â Â Â US PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 26Â Â Â US PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 27Â Â Â US PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 28Â Â Â US PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 29Â Â Â CANADA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 30Â Â Â CANADA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 31Â Â Â CANADA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 32Â Â Â CANADA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 33Â Â Â CANADA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 34Â Â Â CANADA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 35Â Â Â CANADA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 36Â Â Â CANADA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 37Â Â Â MEXICO PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 38Â Â Â MEXICO PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 39Â Â Â MEXICO PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 40Â Â Â MEXICO PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 41Â Â Â MEXICO PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 42Â Â Â MEXICO PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 43Â Â Â MEXICO PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 44Â Â Â MEXICO PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 45Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 46Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 47Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 48Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 49Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 50Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 51Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 52Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 53Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 54Â Â Â SOUTH AMERICA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 55Â Â Â BRAZIL PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 56Â Â Â BRAZIL PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 57Â Â Â BRAZIL PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 58Â Â Â BRAZIL PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 59Â Â Â BRAZIL PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 60Â Â Â BRAZIL PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 61Â Â Â BRAZIL PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 62Â Â Â BRAZIL PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 63Â Â Â ARGENTINA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 64Â Â Â ARGENTINA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 65Â Â Â ARGENTINA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 66Â Â Â ARGENTINA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 67Â Â Â ARGENTINA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 68Â Â Â ARGENTINA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 69Â Â Â ARGENTINA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 70Â Â Â ARGENTINA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 71Â Â Â COLOMBIA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 72Â Â Â COLOMBIA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 73Â Â Â COLOMBIA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 74Â Â Â COLOMBIA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 75Â Â Â COLOMBIA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 76Â Â Â COLOMBIA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 77Â Â Â COLOMBIA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 78Â Â Â COLOMBIA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 79Â Â Â REST OF SOUTH AMERICA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 80Â Â Â REST OF SOUTH AMERICA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 81Â Â Â REST OF SOUTH AMERICA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 82Â Â Â REST OF SOUTH AMERICA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 83Â Â Â REST OF SOUTH AMERICA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 84Â Â Â REST OF SOUTH AMERICA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 85Â Â Â REST OF SOUTH AMERICA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 86Â Â Â REST OF SOUTH AMERICA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 87Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 88Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 89Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 90Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 91Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 92Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 93Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 94Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 95Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 96Â Â Â ASIA-PACIFIC PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 97Â Â Â INDIA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 98Â Â Â INDIA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 99Â Â Â INDIA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 100Â INDIA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 101Â INDIA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 102Â INDIA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 103Â INDIA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 104Â INDIA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 105Â CHINA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 106Â CHINA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 107Â CHINA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 108Â CHINA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 109Â CHINA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 110Â CHINA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 111Â CHINA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 112Â CHINA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 113Â JAPAN PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 114Â JAPAN PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 115Â JAPAN PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 116Â JAPAN PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 117Â JAPAN PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 118Â JAPAN PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 119Â JAPAN PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 120Â JAPAN PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 121Â SOUTH KOREA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 122Â SOUTH KOREA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 123Â SOUTH KOREA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 124Â SOUTH KOREA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 125Â SOUTH KOREA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 126Â SOUTH KOREA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 127Â SOUTH KOREA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 128Â SOUTH KOREA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 129Â AUSTRALIA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 130Â AUSTRALIA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 131Â AUSTRALIA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 132Â AUSTRALIA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 133Â AUSTRALIA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 134Â AUSTRALIA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 135Â AUSTRALIA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 136Â AUSTRALIA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 137Â SOUTH-EAST ASIA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 138Â SOUTH-EAST ASIA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 139Â SOUTH-EAST ASIA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 140Â SOUTH-EAST ASIA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 141Â SOUTH-EAST ASIA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 142Â SOUTH-EAST ASIA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 143Â SOUTH-EAST ASIA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 144Â SOUTH-EAST ASIA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 145Â REST OF ASIA PACIFIC PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 146Â REST OF ASIA PACIFIC PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 147Â REST OF ASIA PACIFIC PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 148Â REST OF ASIA PACIFIC PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 149Â REST OF ASIA PACIFIC PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 150Â REST OF ASIA PACIFIC PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 151Â REST OF ASIA PACIFIC PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 152Â REST OF ASIA PACIFIC PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 153Â EUROPE PRECLINICAL IMAGING MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 154Â EUROPE PRECLINICAL IMAGING MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 155Â EUROPE PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 156Â EUROPE PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 157Â EUROPE PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 158Â EUROPE PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 159Â EUROPE PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 160Â EUROPE PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 161Â EUROPE PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 162Â EUROPE PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 163Â GERMANY PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 164Â GERMANY PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 165Â GERMANY PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 166Â GERMANY PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 167Â GERMANY PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 168Â GERMANY PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 169Â GERMANY PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 170Â GERMANY PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 171Â UK PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 172Â UK PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 173Â UK PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 174Â UK PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 175Â UK PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 176Â UK PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 177Â UK PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 178Â UK PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 179Â FRANCE PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 180Â FRANCE PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 181Â FRANCE PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 182Â FRANCE PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 183Â FRANCE PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 184Â FRANCE PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 185Â FRANCE PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 186Â FRANCE PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 187Â ITALY PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 188Â ITALY PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 189Â ITALY PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 190Â ITALY PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 191Â ITALY PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 192Â ITALY PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 193Â ITALY PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 194Â ITALY PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 195Â SPAIN PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 196Â SPAIN PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 197Â SPAIN PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 198Â SPAIN PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 199Â SPAIN PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 200Â SPAIN PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 201Â SPAIN PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 202Â SPAIN PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 203Â RUSSIA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 204Â RUSSIA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 205Â RUSSIA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 206Â RUSSIA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 207Â RUSSIA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 208Â RUSSIA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 209Â RUSSIA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 210Â RUSSIA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 211Â REST OF EUROPE PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 212Â REST OF EUROPE PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 213Â REST OF EUROPE PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 214Â REST OF EUROPE PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 215Â REST OF EUROPE PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 216Â REST OF EUROPE PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 217Â REST OF EUROPE PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 218Â REST OF EUROPE PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 219Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 220Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 221Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 222Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 223Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 224Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 225Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 226Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 227Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 228Â MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 229Â UAE PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 230Â UAE PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 231Â UAE PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 232Â UAE PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 233Â UAE PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 234Â UAE PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 235Â UAE PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 236Â UAE PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 237Â SAUDI ARABIA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 238Â SAUDI ARABIA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 239Â SAUDI ARABIA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 240Â SAUDI ARABIA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 241Â SAUDI ARABIA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 242Â SAUDI ARABIA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 243Â SAUDI ARABIA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 244Â SAUDI ARABIA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 245Â SOUTH AFRICA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 246Â SOUTH AFRICA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 247Â SOUTH AFRICA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 248Â SOUTH AFRICA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 249Â SOUTH AFRICA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 250Â SOUTH AFRICA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 251Â SOUTH AFRICA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 252Â SOUTH AFRICA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
TABLE 253Â REST OF MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
TABLE 254Â REST OF MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY PRODUCT (THOUSAND UNITS) 2020-2030
TABLE 255Â REST OF MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
TABLE 256Â REST OF MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY REAGANT (THOUSAND UNITS) 2020-2030
TABLE 257Â REST OF MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
TABLE 258Â REST OF MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY APPLICATION (THOUSAND UNITS) 2020-2030
TABLE 259Â REST OF MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
TABLE 260Â REST OF MIDDLE EAST AND AFRICA PRECLINICAL IMAGING MARKET BY END-USE (THOUSAND UNITS) 2020-2030
LIST OF FIGURES
FIGURE 1Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2020-2030
FIGURE 9Â Â Â GLOBAL PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2020-2030
FIGURE 10 GLOBAL PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2020-2030
FIGURE 11 GLOBAL PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2020-2030
FIGURE 12 GLOBAL PRECLINICAL IMAGING MARKET BY REGION (USD BILLION) 2020-2030
FIGURE 13 PORTER’S FIVE FORCES MODEL
FIGURE 14 GLOBAL PRECLINICAL IMAGING MARKET BY PRODUCT (USD BILLION) 2022
FIGURE 15 GLOBAL PRECLINICAL IMAGING MARKET BY REAGANT (USD BILLION) 2022
FIGURE 16 GLOBAL PRECLINICAL IMAGING MARKET BY APPLICATION (USD BILLION) 2022
FIGURE 17 GLOBAL PRECLINICAL IMAGING MARKET BY END-USE (USD BILLION) 2022
FIGURE 18 GLOBAL PRECLINICAL IMAGING MARKET BY REGION (USD BILLION) 2022
FIGURE 19 MARKET SHARE ANALYSIS
FIGURE 20 BRUKER CORPORATION: COMPANY SNAPSHOT
FIGURE 21 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
FIGURE 22 GENERAL ELECTRIC HEALTHCARE: COMPANY SNAPSHOT
FIGURE 23 PERKINELMER, INC.: COMPANY SNAPSHOT
FIGURE 24 VISUALSONICS INC.: COMPANY SNAPSHOT
FIGURE 25 MEDISO LTD.: COMPANY SNAPSHOT
FIGURE 26 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
FIGURE 27 MILABS B.V.: COMPANY SNAPSHOT
FIGURE 28 MR SOLUTIONS LTD.: COMPANY SNAPSHOT
FIGURE 29 TRIFOIL IMAGING, INC.: COMPANY SNAPSHOT
FIGURE 30 MOLECUBES: COMPANY SNAPSHOT
FIGURE 31 ASPECT IMAGING: COMPANY SNAPSHOT
FIGURE 32 LI-COR BIOSCIENCES, INC.: COMPANY SNAPSHOT
FIGURE 33 XACT ROBOTICS: COMPANY SNAPSHOT
FIGURE 34 BRUKER BIOSPIN: COMPANY SNAPSHOT
FIGURE 35 CONCORDE MICROSYSTEMS: COMPANY SNAPSHOT
FIGURE 36 FUJIFILM HEALTHCARE AMERICAS: COMPANY SNAPSHOT
FIGURE 37 GE RESEARCH: COMPANY SNAPSHOT
FIGURE 38 IBA GROUP: COMPANY SNAPSHOT
FIGURE 39 MILABS: COMPANY SNAPSHOT
FAQ
The global preclinical imaging market is expected to grow from USD 4.30 Billion in 2023 to USD 6.08 Billion by 2030, at a CAGR of 5.10 % during the forecast period.
North America accounted for the largest market in the preclinical imaging market. North America accounted for 37 % market share of the global market value.
Bruker Corporation, Siemens Healthineers, General Electric Healthcare, PerkinElmer, Inc., VisualSonics Inc., Mediso Ltd., Agilent Technologies, Inc., MILabs B.V., MR Solutions Ltd., TriFoil Imaging, Inc., Molecubes, Aspect Imaging, Li-COR Biosciences, Inc., XACT Robotics, Bruker BioSpin, Concorde Microsystems, FUJIFILM Healthcare Americas, GE Research, IBA Group, MILabs
The increasing adoption of multimodal imaging techniques that offer a comprehensive view of biological processes in preclinical research. Additionally, there is a growing emphasis on the development of novel imaging probes and contrast agents to enhance the specificity and sensitivity of preclinical imaging modalities.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.